KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
